aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
PharmaCyte Biotech, founded in California, is a pioneering biotechnological and pharmaceutical company focused on developing innovative treatments for cancer and diabetes. Utilizing live-cell encapsulation technology, PharmaCyte aims to enclose living cells within protective capsules to enhance the efficacy and safety of these treatments. Their core mission is to revolutionize the therapeutic landscape for these chronic diseases, providing more effective and targeted solutions for patients worldwide.
Notable figures associated with PharmaCyte Biotech include leading scientists and medical experts who contribute to the development of their cutting-edge technologies. The company has garnered attention from prominent investors in the biotech sector, reflecting confidence in its potential. Key achievements include significant advancements in encapsulation technology and successful preclinical trials. Overall, PharmaCyte Biotech is making a substantial impact on the biotechnology field, offering promising new avenues for treating some of the most challenging medical conditions.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Cancer Treatments, Diabetes Treatments
Technology
Biotech
Tags
Healthtech
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was PharmaCyte Biotech founded?
PharmaCyte Biotech was founded in 1996.
Where is PharmaCyte Biotech’s headquarters located?
PharmaCyte Biotech’s headquarters is located in Las Vegas, NV, US.
When was PharmaCyte Biotech’s last funding round?
PharmaCyte Biotech’s most recent funding round was for $70M (USD) in August 2021.
How many employees does PharmaCyte Biotech have?
PharmaCyte Biotech has 281269 employees as of Feb 5, 2024.
How much has PharmaCyte Biotech raised to-date?
As of July 05, 2023, PharmaCyte Biotech has raised a total of $87.1M (USD) since Aug 19, 2021.
Add Comparison
Total Raised to Date
$87.1M
USD
Last Update Aug 19, 2021
Last Deal Details
$70M
USD
Aug 19, 2021
Post Ipo Equity
Total Employees Over Time
281269
As of Feb 2024
PharmaCyte Biotech Address
3960 Howard Hughes Parkway
Suite 500
Las Vegas,
Nevada
89109
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts